On paper, things should be looking up for Japan’s pharmaceutical wholesalers. Industry expectations are mounting that the average gap between NHI and market prices will narrow further in FY2026 from the previous year’s record low of 4.8%.A shrinking gap should…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Astellas Sees Sales Decline through FY2029 on Xtandi LOE, Maps 200 Billion Yen Cuts in 5 Years
May 27, 2026
-
REGULATORY LDP Panel OKs Immunization Act Bill Aimed at Beyfortus NIP Use
May 27, 2026
-
REGULATORY US Calls Out Japan’s Market Expansion Re-Pricing Rules as “Unfair”: IP Report
May 26, 2026
-
COMMENTARY Are Technical Discussions Enough for Japan’s CEA System?
May 25, 2026
-
BUSINESS Japan Market Hits Record 11.8 Trillion Yen in FY2025, Keytruda Keeps Title: IQVIA
May 22, 2026
-
BUSINESS Kissei Drops Call to Halt New Tavneos Use after Blue Letter Action
May 22, 2026
-
REGULATORY Update: Tavneos Slapped with Blue Letter Action in Japan over Liver Injury Risk
May 22, 2026
-
ORGANIZATION Novartis’ Pullicino to Helm EFPIA Japan from July
May 22, 2026
-
BUSINESS BMS, Nikon Pitch Japan-to-Asia Cell Therapy Push, Draw Support at Policy Forum
May 21, 2026
-
BUSINESS Sanofi Eyes Double-Digit Annual Growth for Japan Vaccine Business: Exec
May 20, 2026
-
REGULATORY Japan to Start CEA Technical Discussions as Early as May 25
May 20, 2026
-
REGULATORY Japan Approves Jascayd, mNEXSPIKE, Zepbound OSA Use, Others
May 19, 2026
-
REGULATORY Wegovy’s MASH Label Expansion and More Up for Japan Panel Review on May 29
May 18, 2026
-
BUSINESS Kissei Urges Halt to New Tavneos Use after Fatal Liver Injury Reports
May 18, 2026
-
REGULATORY MHLW Official Says US MFN Policy Could Be Taken Up by Chuikyo
May 15, 2026
-
REGULATORY Japan to Launch CEA “Technical Discussions” under MHLW Research Group
May 14, 2026
-
REGULATORY Mounjaro Hit with 25% Price Cut under Japan’s “SPA-SSS” Re-Pricing
May 14, 2026
-
REGULATORY Japan OKs Listing of Ambelvist, Dojolvi, Sohonos, and Finally Inrebic
May 14, 2026
-
REGULATORY Chuikyo Clears NHI Listing for Amchepry, Akuugo, and Zolgensma Intrathecal
May 14, 2026
-
REGULATORY Japan to Finalize 1st ALS Trial Guidelines This Year to Spur Global Development
May 13, 2026
ページ
Tariffs have been a defining feature of US trade policy under President Donald Trump’s second administration. Since Trump unveiled his “reciprocal” tariff policy in April 2025, the landscape has shifted repeatedly.In February 2026, the US Supreme Court invalidated tariffs imposed…
As Japan’s budget season draws near, the Ministry of Finance (MOF) has renewed its push for a full-scale “off-year” drug…
Japan will trim the NHI price of Eli Lilly Japan’s Alzheimer’s treatment Kisunla (donanemab) by 3.93% under the cost-effectiveness assessment…
Japan is set to add 16 new drugs to its NHI reimbursement price list on November 13, including a subcutaneous…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…